Skip to main content
HeartCited

Nattokinase ： High Blood Pressure (Hypertension)

C

Modest BP reduction (systolic -3.5 mmHg). Fibrinolytic mechanism may contribute to vascular effects. Larger confirmatory trials are needed.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dnattokinase\u0026condition\u003Dhigh\u002Dblood\u002Dpressure'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            C

        

        

            
結論

            
            
Modest BP reduction (systolic -3.5 mmHg). Fibrinolytic mechanism may contribute to vascular effects. Larger confirmatory trials are needed.

            
            
        

    











    
    

        
        

            

  
Key Statistics





            


    

        
6

        
研究数

    

    

        
400

        
参加者数

    

    

        
            
            ↑
            
        
        
Positive

    

    

        C

        
グレード

    




        


        
        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
一般的な使用量

                

                    
                    

                        
general:

                        
2,000 FU (fibrinolytic units)/day

                    

                    
                    

                        
cardiovascularsupport:

                        
2,000-4,000 FU/day

                    

                    
                

                
                

                    上限量： Not formally established; up to 10,800 FU/day used in clinical trials
                

                
            

            

            

            
            

                推奨摂取タイミング： On empty stomach (between meals) for optimal fibrinolytic activity
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
報告されている副作用

                    
    
                        
                        
  • 
                            ⚠
                            Generally well-tolerated
                        
    • 
                        
                        
  • 
                            ⚠
                            Increased bleeding risk (fibrinolytic activity)
                        
    • 
                        
                        
  • 
                            ⚠
                            Mild gastrointestinal discomfort
                        
    • 
                        
                        
  • 
                            ⚠
                            Bruising (rare)
                        
    • 
                        
                    

                

                

                
                

                    
既知の相互作用

                    
    
                        
                        
  • 
                            ●
                            Anticoagulants — warfarin, DOACs (additive anticoagulant effects — contraindicated)
                        
    • 
                        
                        
  • 
                            ●
                            Antiplatelet drugs (additive bleeding risk)
                        
    • 
                        
                        
  • 
                            ●
                            NSAIDs (increased bleeding risk)
                        
    • 
                        
                        
  • 
                            ●
                            Fish oil at high doses (additive anticoagulant effect)
                        
    • 
                        
                    

                

                

                
                

                    

                        耐容上限摂取量： Not formally established; up to 10,800 FU/day used in clinical trials
                    

                

                
            

            

                サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Nattokinase help with High Blood Pressure (Hypertension)?
            
        
        

            Based on 6 studies with 400 participants, there is limited but promising evidence that Nattokinase may support High Blood Pressure (Hypertension) management. Our evidence grade is C (Some Evidence).
        

    

    
    

        
            How much Nattokinase should I take for High Blood Pressure (Hypertension)?
            
        
        

            Studies have used various dosages. A commonly studied range is 2,000 FU (fibrinolytic units)/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Nattokinase?
            
        
        

            Reported side effects may include Generally well-tolerated, Increased bleeding risk (fibrinolytic activity), Mild gastrointestinal discomfort, Bruising (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Nattokinase and High Blood Pressure (Hypertension)?
            
        
        

            We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                
                

                
                

                    
Nattokinase 他の症状・状態について

                    

                        
                        
                            Atherosclerosis
                            B

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDAに関する免責事項:
        これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。